BioNTech Management

Management criteria checks 4/4

BioNTech's CEO is Ugur Sahin, appointed in Jan 2008, has a tenure of 16.83 years. total yearly compensation is €3.06M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 17.23% of the company’s shares, worth €4.49B. The average tenure of the management team and the board of directors is 3.3 years and 4.6 years respectively.

Key information

Ugur Sahin

Chief executive officer

€3.1m

Total compensation

CEO salary percentage	22.9%
CEO tenure	16.8yrs
CEO ownership	17.2%
Management average tenure	3.3yrs
Board average tenure	4.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ugur Sahin's remuneration changed compared to BioNTech's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-€467m
Jun 30 2024	n/a	n/a	-€504m
Mar 31 2024	n/a	n/a	€113m
Dec 31 2023	€3m	€700k	€930m
Sep 30 2023	n/a	n/a	€3b
Jun 30 2023	n/a	n/a	€4b
Mar 31 2023	n/a	n/a	€6b
Dec 31 2022	€6m	€360k	€9b
Sep 30 2022	n/a	n/a	€10b
Jun 30 2022	n/a	n/a	€12b
Mar 31 2022	n/a	n/a	€13b
Dec 31 2021	€12m	€360k	€10b
Sep 30 2021	n/a	n/a	€7b
Jun 30 2021	n/a	n/a	€4b
Mar 31 2021	n/a	n/a	€1b
Dec 31 2020	€17m	€360k	€15m
Sep 30 2020	n/a	n/a	-€410m
Jun 30 2020	n/a	n/a	-€230m
Mar 31 2020	n/a	n/a	-€192m
Dec 31 2019	€7m	€311k	-€179m
Sep 30 2019	n/a	n/a	-€122m
Jun 30 2019	n/a	n/a	-€116m
Mar 31 2019	n/a	n/a	-€77m
Dec 31 2018	€653k	€210k	-€48m

Compensation vs Market: Ugur's total compensation ($USD3.18M) is below average for companies of similar size in the German market ($USD4.78M).

Compensation vs Earnings: Ugur's compensation has been consistent with company performance over the past year.

CEO

Ugur Sahin (59 yo)

16.8yrs

Tenure

€3,056,000

Compensation

Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ugur Sahin	Co-Founder	16.8yrs	€3.06m	17.23% € 4.5b
Ozlem Tureci	Co-Founder	6.8yrs	€814.00k	0.38% € 99.2m
Jens Holstein	CFO & Member of Management Board	3.3yrs	€1.32m	0.00068% € 177.1k
Sierk Poetting	MD, COO & Member of Management Board	10.8yrs	€821.00k	0.31% € 82.0m
Ryan Richardson	Chief Strategy Officer	4.8yrs	€1.41m	0.0061% € 1.6m
James Timothy Ryan	Chief Legal & Business Officer & Member of the Management Board	1.2yrs	€848.00k	no data
Sean Marett	Executive Officer	less than a year	€133.00k	0.34% € 88.6m
Lisa Birringer	Senior Vice President of Global Financial Reporting & Accounting	less than a year	no data	no data
Zach Taylor	Senior Vice President of Corporate Development & Strategy	less than a year	no data	no data
Katalin Kariko	Senior VP & External Consultant for RNA Protein Replacement Therapies	no data	no data	no data
Oliver Henning	Senior Vice President of Operations	no data	no data	no data
Sebastian Kreiter	Senior Vice President of Immunotherapy & Preclinical Research	no data	no data	no data

3.3yrs

Average Tenure

57yo

Average Age

Experienced Management: 22UA's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Rudolf Staudigl	Supervisory Board Member	2.4yrs	€90.00k	0.00017% € 44.3k
Ulrich Wandschneider	Independent Deputy Chairman Supervisory Board	6.8yrs	€114.00k	no data
Michael Motschmann	Independent Supervisory Board Member	16.8yrs	€80.00k	no data
Helmut Jeggle	Independent Supervisory Board Chairman	16.8yrs	€226.00k	0.14% € 36.1m
Nicola Blackwood	Member of Supervisory Board	1.5yrs	€46.00k	no data
Anja Morawietz	Supervisory Board Member	2.4yrs	€105.00k	0.00010% € 26.0k

4.6yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 22UA's board of directors are considered experienced (4.6 years average tenure).

BioNTech Management

Management criteria checks 4/4

Key information

Recent management updates

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE, Annual General Meeting, May 17, 2024

Recent updates

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: EPS: €0.82 (vs €0.67 in 3Q 2023)

BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024

BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

New major risk - Revenue and earnings growth

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbH

Second quarter 2024 earnings released: €3.36 loss per share (vs €0.79 loss in 2Q 2023)

BioNTech SE Reiterates Earnings Guidance for the Year 2024

BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: €1.31 loss per share (vs €2.07 profit in 1Q 2023)

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

Now 20% undervalued after recent price drop

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: €3.87 (vs €38.78 in FY 2022)

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Third quarter 2023 earnings released: EPS: €0.67 (vs €7.43 in 3Q 2022)

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Investor sentiment deteriorates as stock falls 15%

New minor risk - Share price stability

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age